Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Human Papillomavirus Vaccines
Reports from E.H. Elbasha and co-researchers add new data to research in human papillomavirus vaccines
June 18th, 2008
"Human papillomavirus (HPV) is the primary cause of cervical carcinoma and its precursor lesions, and is associated with a variety of other cancers and diseases. A prophylactic quadrivalent vaccine against oncogenic HPV 16/18 and warts-causing genital HPV 6/11 types is currently available in several countries," investigators in the United States report. "Licensure of a bivalent vaccine against oncogenic HPV 16/18 is expected in the near future. This paper presents a two-sex, deterministic model for assessing the potential impact of a prophylactic HPV vaccine with several properties. The model is based on the susceptible-infective-removed (SIR) compartmental structure....
Source: Vaccine Weekly (2008-06-18)
|
